Change in management at GILUPI GmbH

Alexander Herrmann starts as new managing director at the medical device company

Potsdam, (PresseBox) - With immediate effect, Alexander Herrmann will be responsible as managing director of medical device company, located in Potsdam and Greifswald. He succeeds Klaus Lücke, who is leaving GILUPI after more than 10 years to move on to new professional challenges.

Having a master degree in Business Administration, Alexander Herrmann (43) counts many years of experience in leadership at biotechnology companies. He is supposed to speed-up the GILUPI CellCollector® marketing as well as the necessary restructuring of the company.

Mr. Herrmann commented: “The GILUPI CellCollector® is a unique and innovative product. Our target for the coming months is to enhance the GILUPI CellCollector® application by adding further molecular analytical tools, thus making the application even more valuable for our customers. Moreover, we will upscale our production capacity in Greifswald and complement our team by additional experts.

Website Promotion


GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.

Individual oncological targeted therapies will become more and more important in tomorrow's personalized medicine. The identification of the right drug for the specific patient is the upcoming challenge. To address this medical need, the application of the GILUPI CellCollector® enriches rare cells (circulating tumor cells - CTCs) by directly "fishing" them in the patient's bloodstream. By using special diagnostic analyses, these isolated cells can be characterized and/or analyzed at a molecular level.

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide that is CE approved.

For further information visit

Press releases you might also be interested in

Weitere Informationen zum Thema "Medizintechnik":

Künstliche Intelligenz in der Cybersecurity

Der der­zeit heiß dis­ku­tier­te Ein­satz künst­li­cher In­tel­li­genz in der Cy­berse­cu­ri­ty weckt Be­gehr­lich­kei­ten: All­zu­gern wür­den man­che An­wen­der den Groß­teil der teu­ren und zer­mür­ben­den Ar­beit im SOC kom­p­lett den KI-Sys­te­men über­las­sen. Wir­k­lich schlag­kräf­tig und hin­rei­chend ne­ben­wir­kungs­f­rei ar­bei­tet KI aber nur im Team mit men­sch­li­cher In­tel­li­genz.


Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.